welcome
TipRanks

TipRanks

Health

Health

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi

TipRanks
Summary
Nutrition label

87% Informative

Exelixis (EXEL) announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx , for the treatment of unresectable, locally advanced or metastatic pancreatic neuroendocrine tumors and extra-pancreatic NET in patients ages 12 or older.

The approval is “certainly positive” for the stock, Citi analyst David Lebowitz tells investors in a research note.

VR Score

83

Informative language

80

Neutral language

79

Article tone

formal

Language

English

Language complexity

74

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

Affiliate links

no affiliate links

Small business owner?

Otherweb launches Autoblogger—a revolutionary way to bring more leads to any small business, using the power of AI.